Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 196 to 210 of 1037 results for criteria

  1. Bevacizumab in combination with a taxane for the first-line treatment of metastatic breast cancer (TA214)

    Evidence-based recommendations on bevacizumab (Avastin), with a taxane, for treating metastatic breast cancer in adults.

    Technology appraisal guidance
    Published
    23 February 2011
    View recommendations

    Sections for TA214

  2. Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma (TA540)

    Evidence-based recommendations on pembrolizumab (Keytruda) for treating relapsed or refractory classical Hodgkin lymphoma in adults.

    Technology appraisal guidance
    Last updated
    1 May 2024
    View recommendations

    Sections for TA540

  3. Good practice guidance – Interim process statement (PMG3)

    Good practice guidance – Interim process statement

  4. Referral criteria for joint replacement: What are the most important indicators that someone with osteoarthritis (including shoulder osteoarthritis) would benefit from joint replacement? For example: - presence of night pain - non-response to non-pharmacological interventions - joint instability symptoms - presence of flares - numerical summary scores.

    Recommendation ID NG226/12 Question Referral criteria for joint replacement: What are the most important indicators that someone with...

    Research recommendation
    Published
    7 November 2022

  5. NICE encourages further research into focal cryoablation for localised prostate cancer. This should take the form of controlled studies comparing the procedure against other forms of management. Studies should clearly define patient selection criteria and should report outcomes including local recurrence in the long term.

    other forms of management. Studies should clearly define patient selection criteria and should report outcomes including local...

    Research recommendation
    Published
    9 June 2015

  6. Guselkumab for treating moderate to severe plaque psoriasis (TA521)

    Evidence-based recommendations on guselkumab (Tremfya) for treating moderate to severe plaque psoriasis in adults.

    Technology appraisal guidance
    Published
    13 June 2018
    View recommendations

    Sections for TA521

  7. Secukinumab for treating moderate to severe plaque psoriasis in children and young people (TA734)

    Evidence-based recommendations on secukinumab (Cosentyx) for moderate to severe plaque psoriasis in children and young people aged 6 to 17 years.

    Technology appraisal guidance
    Published
    7 October 2021
    View recommendations

    Sections for TA734

  8. Entrectinib for treating NTRK fusion-positive solid tumours (TA644)

    Evidence-based recommendations on entrectinib (Rozlytrek) for treating neurotrophic tyrosine receptor kinase (NTRK) fusion-positive solid tumours in adults and children over 12 years.

    Technology appraisal guidance
    Published
    12 August 2020
    View recommendations

    Sections for TA644

  9. Lenalidomide with rituximab for previously treated follicular lymphoma (TA627)

    Evidence-based recommendations on lenalidomide (Revlimid) with rituximab for previously treated follicular lymphoma (grade 1 to 3A) in adults.

    Technology appraisal guidance
    Published
    7 April 2020
    View recommendations

    Sections for TA627

  10. Ipilimumab for previously treated advanced (unresectable or metastatic) melanoma (TA268)

    Evidence-based recommendations on ipilimumab (Yervoy) for previously treated advanced melanoma in adults.

    Technology appraisal guidance
    Published
    12 December 2012
    View recommendations

    Sections for TA268

  11. Dupilumab for treating moderate to severe prurigo nodularis (TA955)

    Evidence-based recommendations on dupilumab (Dupixent) for treating moderate to severe prurigo nodularis in adults when systemic treatment is suitable.

    Technology appraisal guidance
    Published
    13 March 2024
    View recommendations

    Sections for TA955

  12. The Sherlock 3CG Tip Confirmation System for placement of peripherally inserted central catheters (MTG24)

    Evidence-based recommendations on The Sherlock 3CG Tip Confirmation System for placement of peripherally inserted central catheters.

    Medical technologies guidance
    Last updated
    30 May 2019
    View recommendations

    Sections for MTG24

  13. Axicabtagene ciloleucel for treating diffuse large B-cell lymphoma and primary mediastinal large B-cell lymphoma after 2 or more systemic therapies (TA872)

    Evidence-based recommendations on axicabtagene ciloleucel (Yescarta) for treating diffuse large B-cell lymphoma and primary mediastinal large B-cell lymphoma in adults after 2 or more systemic therapies.

    Technology appraisal guidance
    Published
    28 February 2023

    Sections for TA872

  14. Medical Technologies Evaluation Programme

    How to submit a new medical technology to NICE for guidance

  15. Everolimus for advanced renal cell carcinoma after previous treatment (TA432)

    Evidence-based recommendations on everolimus (Afinitor) for advanced renal cell carcinoma after previous treatment.

    Technology appraisal guidance
    Published
    22 February 2017
    View recommendations

    Sections for TA432